Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.

Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, Pozzoni P, Giorgini A, Fabris P, Romano A, Lomonaco L, Puoti M, Vinci M, Gatti F, Carolo G, Zoncada A, Bonfanti P, Russo FP, Aghemo A, Soria A, Centenaro R, Maggiolo F, Rovere P, Pasin F, Paon V, Faggiano G, Vario A, Grossi G, Soffredini R, Carriero C, Paolucci S, Noventa F, Alberti A, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia and Veneto Study Groups.

J Hepatol. 2019 Dec;71(6):1106-1115. doi: 10.1016/j.jhep.2019.07.020. Epub 2019 Aug 6.

PMID:
31433303
2.

TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals.

Degasperi E, Galmozzi E, Facchetti F, Farina E, D'Ambrosio R, Soffredini R, Iavarone M, Lampertico P.

J Viral Hepat. 2019 Oct;26(10):1233-1236. doi: 10.1111/jvh.13155. Epub 2019 Jun 30.

PMID:
31177595
3.

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study.

Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuismink ZMA, Santoro R, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA; GIANT-B Global Consortium .

Clin Infect Dis. 2019 Nov 13;69(11):1969-1979. doi: 10.1093/cid/ciz084.

4.

Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.

Degasperi E, D'Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, Borghi M, Lunghi G, Colombo M, Lampertico P.

Clin Gastroenterol Hepatol. 2019 May;17(6):1183-1191.e7. doi: 10.1016/j.cgh.2018.10.038. Epub 2018 Oct 26.

PMID:
30613002
5.

Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance.

Grossi G, Loglio A, Facchetti F, Borghi M, Soffredini R, Galmozzi E, Lunghi G, Gaggar A, Lampertico P.

J Hepatol. 2017 Sep 21. pii: S0168-8278(17)32260-2. doi: 10.1016/j.jhep.2017.08.020. [Epub ahead of print]

PMID:
28870666
6.

Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection.

Aghemo A, Degasperi E, De Nicola S, Bono P, Orlandi A, D'Ambrosio R, Soffredini R, Perbellini R, Lunghi G, Colombo M.

Clin Gastroenterol Hepatol. 2016 Sep;14(9):1331-6. doi: 10.1016/j.cgh.2016.03.035. Epub 2016 Apr 1.

PMID:
27046484
7.

Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.

Cheroni C, Donnici L, Aghemo A, Balistreri F, Bianco A, Zanoni V, Pagani M, Soffredini R, D'Ambrosio R, Rumi MG, Colombo M, Abrignani S, Neddermann P, De Francesco R.

PLoS One. 2015 Sep 25;10(9):e0138546. doi: 10.1371/journal.pone.0138546. eCollection 2015.

8.

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.

Aghemo A, Grassi E, Rumi MG, D'Ambrosio R, Galmozzi E, Degasperi E, Castaldi D, Soffredini R, Colombo M.

PLoS One. 2014 Apr 23;9(4):e95881. doi: 10.1371/journal.pone.0095881. eCollection 2014.

9.

Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients.

Degasperi E, Valenti L, Aghemo A, De Francesco R, Rumi M, Soffredini R, Donnici L, Cheroni C, Fargion S, Zanoni V, Orsi E, Colombo M.

Antivir Ther. 2014;19(8):747-53. doi: 10.3851/IMP2743. Epub 2014 Feb 12.

PMID:
24523350
10.

Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.

Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M.

Hepatology. 2012 Nov;56(5):1681-7. doi: 10.1002/hep.25867. Epub 2012 Oct 14.

PMID:
22619107
11.

IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.

Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abrignani S, De Francesco R, Colombo M.

Hepatology. 2013 Mar;57(3):890-6. doi: 10.1002/hep.25749. Epub 2012 Dec 20.

PMID:
22473858
12.

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M.

Hepatology. 2012 Feb;55(2):336-42. doi: 10.1002/hep.24683. Epub 2012 Jan 3.

PMID:
21932415
13.

Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection.

Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M.

Hepatology. 2011 Oct;54(4):1127-34. doi: 10.1002/hep.24503. Epub 2011 Aug 19.

PMID:
21721028
14.

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M.

Gastroenterology. 2010 Jan;138(1):108-15. doi: 10.1053/j.gastro.2009.08.071. Epub 2009 Sep 18.

PMID:
19766645
15.

Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.

Aghemo A, Rumi MG, Soffredini R, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M.

Antivir Ther. 2006;11(6):797-802.

PMID:
17310824
16.

The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study.

Federici AB, Santagostino E, Rumi MG, Russo A, Mancuso ME, Soffredini R, Mannucci PM, Colombo M.

Haematologica. 2006 Apr;91(4):503-8.

17.

Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy.

Soffredini R, Rumi MG, Parravicini ML, Ronchi G, Del Ninno E, Russo A, Colombo M.

Am J Gastroenterol. 2004 Sep;99(9):1738-43.

PMID:
15330912
18.

High prevalence, low pathogenicity of hepatitis G virus in kidney transplant recipients.

De Filippi F, Lampertico P, Soffredini R, Rumi MG, Lunghi G, Aroldi A, Tarantino A, Ponticelli C, Colombo M.

Dig Liver Dis. 2001 Aug-Sep;33(6):477-9.

PMID:
11572574
19.

Serum levels of hepatitis C virus RNA predict non-response to interferon therapy: comparison of two commercial assays.

Soffredini R, Rumi MG, Del Ninno E, Parravicini ML, Russo A, Colombo M.

J Viral Hepat. 1999 Jan;6(1):65-71.

PMID:
10847132
20.

Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination.

Gerken G, Rothaar T, Rumi MG, Soffredini R, Trippler M, Blunk MJ, Butcher A, Soviero S, Colucci G.

J Clin Microbiol. 2000 Jun;38(6):2210-4.

21.

Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity?

Pontisso P, Bellati G, Brunetto M, Chemello L, Colloredo G, Di Stefano R, Nicoletti M, Rumi MG, Ruvoletto MG, Soffredini R, Valenza LM, Colucci G.

Hepatology. 1999 Feb;29(2):585-9.

PMID:
9918939
22.

High prevalence but low pathogenicity of hepatitis G virus infection in Italian patients with genetic haemochromatosis.

De Filippi F, Fraquelli M, Conte D, Soffredini R, Prati D, Ronchi G, Zanella A, Del Ninno E, Colombo M.

Ital J Gastroenterol Hepatol. 1998 Oct;30(5):529-33.

PMID:
9836112
23.

Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor.

De Filippi F, Castelli R, Cicardi M, Soffredini R, Rumi MG, Silini E, Mannucci PM, Colombo M.

Transfusion. 1998 Mar;38(3):307-11.

PMID:
9563413
24.

A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.

Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Wilber J, Russo A, Colombo M.

Hepatology. 1996 Dec;24(6):1366-70.

PMID:
8938163
25.

Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays.

Soffredini R, Rumi M, Lampertico P, Aroldi A, Tarantino A, Ponticelli C, Colombo M.

Am J Kidney Dis. 1996 Sep;28(3):437-40.

PMID:
8804244
26.

Lack of association between type of hepatitis C virus, serum load and severity of liver disease.

Romeo R, Colombo M, Rumi M, Soffredini R, Del Ninno E, Donato MF, Russo A, Simmonds P.

J Viral Hepat. 1996 Jul;3(4):183-90.

PMID:
8871879
27.

Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial.

Rumi MG, del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Zahm F, Colombo M.

J Viral Hepat. 1995;2(2):73-6.

PMID:
7493300
28.

A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.

Lampertico P, Rumi M, Romeo R, Craxì A, Soffredini R, Biassoni D, Colombo M.

Hepatology. 1994 Jan;19(1):19-22.

PMID:
7506225

Supplemental Content

Loading ...
Support Center